Prof. Dr. Kenneth Blum

Western University Health Sciences, USA

Email: drd2gene@gmail.com

Qualifications

1972 Post Doctorate, Texas Biomedical Research Institute, USA

1968 Ph.D., New York Medical College, USA

1965 M.S., The University of Medicine and Dentistry of New Jersey, USA

1961 B.S., Columbia University, USA

Publications (Selected)

1. Madigan MA, Badgaiyan RD, Baron D, Blum, K., Precision Behavioral Management (PBM) A Novel Approach to Combat Post-Traumatic Stress Disorder (PTSD). SOJ Psychol. 2018;5(2):10.15226/2374-6874/5/2/00148. doi: 10.15226/2374-6874/5/2/00148. Epub 2018 Aug 6. PMID: 31440582; PMCID: PMC6706091.
2. Downs BW, Kushner S, Bagchi M, Blum K., Badgaiyan RD, Bagchi D. Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise. Current Psychopharmacology, 2021, 10, 1-15 1.
3. Blum K, Thanos PK, Oscar-Berman M, Febo M, Baron D, Badgaiyan RD, Gardner E, Demetrovics Z, Fahlke C, Haberstick BC, Dushaj K, Gold MS. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. J Reward Defic Syndr. 2015;1(3):95-104. doi: 10.17756/jrds.2015-016. Epub 2015 Oct 23. PMID: 27398406; PMCID: PMC4936401.
4. Blum K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci. 2021 Jan 15;420:117252. doi: 10.1016/j.jns.2020.117252. Epub 2020 Nov 28. PMID: 33279726.
5. Blum K, Morgan J, Cadet JL, Baron D, Carney PR, Khalsa J, Badgaiyan RD, Gold MS. Psychoactive Drugs Like Cannabis -Induce Hypodopaminergic Anhedonia and Neuropsychological Dysfunction in Humans: Putative Induction of Dopamine Homeostasis via Coupling of Genetic Addiction Risk Severity (GARS) testing and Precision Pro-dopamine Regulation (KB220). Neurology (ECronicon). 2021 Apr;13(4):86-92. Epub 2021 Mar 31. PMID: 34085060; PMCID: PMC8171216.
6. Blum K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. J Pers Med. 2021 Mar 16;11(3):212. doi: 10.3390/jpm11030212. PMID: 33809702; PMCID: PMC8002215.
7. Moran M, Blum K, Ponce JV, Lott L, Gondré-Lewis MC, Badgaiyan S, Brewer R, Downs BW, Fynman P, Weingarten A, Cadet JL, Smith DE, Baron D, Thanos PK, Modestino EJ, Badgaiyan RD, Elman I, Gold MS. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. Mol Neurobiol. 2021 Jul;58(7):3335-3346. doi: 10.1007/s12035-021-02312-1. Epub 2021 Mar 8. PMID: 33683627; PMCID: PMC8257535.
8. Blum K, Khalsa J, Cadet JL, Baron D, Bowirrat A, Boyett B, Lott L, Brewer R, Gondré-Lewis M, Bunt G, Kazmi S, Gold MS. Cannabis-Induced Hypodopaminergic Anhedonia and Cognitive Decline in Humans: Embracing Putative Induction of Dopamine Homeostasis. Front Psychiatry. 2021 Mar 30;12:623403. doi: 10.3389/fpsyt.2021.623403. PMID: 33868044; PMCID: PMC8044913.
9. Blum K, Raza A, Schultz T, Jalali R, Green R, Brewer R, Thanos PK, McLaughlin T, Baron D, Bowirrat A, Elman I, Downs BW, Bagchi D, Badgaiyan RD. Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality? Acta Sci Neurol. 2021 Feb 2;4(2):17-24. PMID: 33681869; PMCID: PMC7931265.
10. Richardson B, Swenson S, Hamilton J, Leonard K, Delis F, Gold M, Blum K, Thanos PK. Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 25;112:110407. doi: 10.1016/j.pnpbp.2021.110407. Epub ahead of print. PMID: 34320402.
11. Brittany Richardson, Sabrina Swenson, John Hamilton, Ken Leonard, Foteini Delis, Mark Gold, Ken Blum, Panayotis K. Thanos,Chronic neuroleptic treatment combined with a high fat diet elevated [3H] flunitrazepam binding in the cerebellum,Progress in Neuro-Psychopharmacology and Biological Psychiatry,Volume 112,2022,110407,ISSN 0278-5846,https://doi.org/10.1016/j.pnpbp.2021.110407.
12. Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Postgrad Med. 2010 Nov;122(6):214-26. doi: 10.3810/pgm.2010.11.2237. PMID: 21084796.
13. Blum K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. Journal of Personalized Medicine. 2021; 11(3):212. https://doi.org/10.3390/jpm11030212.